These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37462037)

  • 1. Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia.
    Zhao X; Wu H; Cheng Y; Xu Z; Chen Y; Chang Y; Wang Y; Zhang X; Xu L; Huang X
    Chin Med J (Engl); 2023 Aug; 136(16):2011-2013. PubMed ID: 37462037
    [No Abstract]   [Full Text] [Related]  

  • 2. Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion.
    Ni F; Yin ETS; Zhou L; Zhao H; Luo Y; Shi J; Hu Y; Huang H
    Bone Marrow Transplant; 2022 Feb; 57(2):326-328. PubMed ID: 35067672
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful chimeric antigen receptor T cells therapy in extramedullary relapses of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Zhang H; Hu Y; Wei G; Wu W; Huang H
    Bone Marrow Transplant; 2020 Jul; 55(7):1476-1478. PubMed ID: 31848448
    [No Abstract]   [Full Text] [Related]  

  • 4. HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation.
    Jin X; Cao Y; Wang L; Sun R; Cheng L; He X; Xiao X; Jiang Y; Li Q; Zhang H; Lu W; Lyu C; Jiang Y; Meng J; Zhao M
    Leukemia; 2020 Mar; 34(3):909-913. PubMed ID: 31628429
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
    Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report.
    Wen S; Niu Z; Xing L; Wang Y; Li H; Kuang N; Luo J; Zhang X; Wang F
    BMC Cancer; 2018 Nov; 18(1):1143. PubMed ID: 30458755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation.
    Xu Q; Xu H; Xue L; Wang M; Pan G; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Xu H; Liu X; Zhu X; Sun Z; Yang L; Wang X
    Chin Med J (Engl); 2022 Jan; 135(1):98-100. PubMed ID: 33967196
    [No Abstract]   [Full Text] [Related]  

  • 9. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2017 Oct; 9(13):1115-1125. PubMed ID: 29032733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL).
    Shouse G; Budde E; Forman S
    Cancer Treat Res; 2021; 181():179-196. PubMed ID: 34626362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. InsT-ALLing CD7 chimeric antigen receptors before transplantation.
    Delgado J
    Br J Haematol; 2024 Jun; 204(6):2155-2156. PubMed ID: 38676290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.
    Li Z; Meng F; Li J; Wu T
    Front Immunol; 2022; 13():931452. PubMed ID: 35903089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yao Z; Gu B; Zhang Y; Qi J; Chen J; Xu Y; Chen F; Ma X; Miao M; Xue S; Qiu H; Tang X; Han Y; Chen S; Sun A; Yu L; Wu D; Wang Y
    Bone Marrow Transplant; 2023 Jan; 58(1):103-105. PubMed ID: 36253466
    [No Abstract]   [Full Text] [Related]  

  • 14. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
    Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
    J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent research on chimeric antigen receptor T cells in children with refractory/relapsed acute lymphoblastic leukemia].
    Wei N; Chen TP
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Feb; 25(2):210-216. PubMed ID: 36854700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
    Yang TT; Meng Y; Kong DL; Wei GQ; Zhang MM; Wu WJ; Shi JM; Luo Y; Zhao YM; Yu J; Jing RR; Zhao MY; Zhao HL; Huang H; Hu YX
    Front Immunol; 2022; 13():934442. PubMed ID: 36110859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy?
    Taraseviciute A; Broglie L; Phelan R; Bhatt NS; Becktell K; Burke MJ
    J Pediatr Hematol Oncol; 2019 Jul; 41(5):337-344. PubMed ID: 30973486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.